Grace Therapeutics, Inc.
GRCE
Last
$2.08
Day
+2.0%
1y
-32.5%
5y
-81.9%
52w
-60.6%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
2.10
EMA 50
2.17
EMA 200
2.64
20d high
-12.1%
5y high
-82.8%
5y range
3th
Positions held
Your positionsGRCE isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-30
Hold
avoid
Signal
Strong Sell
Target
$2.18
Stop
$1.92
Stop distance
7.7%
Target vs last
+4.8%
Fundamentals
| Market cap | $42.91M | Enterprise value | $29.16M | Trailing P/E | — | Forward P/E | -4.55 |
| PEG | — | Price / book | 0.69 | Beta | 0.33 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -36.2% | ROA | -10.8% | Debt / equity | — |
| Current ratio | 11.47 | Free cash flow | -$7.00M | Analyst recommendation | none | Mean target | $5.86 |
| 52w high | $5.18 | 52w low | $1.79 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$15.8M | -$1.2M | -$2.3M | -$0.9M | -$3.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.4M | -$3.0M | -$2.4M | -$2.5M | -$3.1M | — |
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$7.8M | -$9.6M | -$12.9M | -$42.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | $0.0M |
| Operating income | -$11.1M | -$16.7M | -$11.4M | -$18.2M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-03 · Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
2026-08-24 · Grace Therapeutics Files for Resale of Up to 4.8 Million Shares
2026-08-13 · Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
2026-08-05 · Grace Therapeutics Announces $10 Million Private Placement
2026-07-28 · Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
Price (daily)
Full chart · RSI · MACD · patternsGRCE · daily-4.7% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin